- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04918836
Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer (IMMUNO-PREDICT)
Immunological Markers Predictive of Response and Toxicity to Checkpoint in Metastatic Non-Small-cell Lung Cancers
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The study will run for 12 months with a 6-month follow-up at the inclusion of the last patient.
Patients will be included from the initiation of immunotherapy treatment regardless of the line.The routine immunological workup will be performed before the first immunotherapy infusion in order to analyze a certain number of immunological markers (autoantibodies, RF, LDH, complement (C3 C4), anti-tissue antibodies, lymphocyte immunophenotyping). This assessment will then be performed at progression, at the appearance of side effects requiring the immunotherapy to be stopped, or at 6 months of follow-up in case of continuation of the immunotherapy.
The investigators will evaluate the response to the treatment, the progression via re-evaluation assessments performed in standard practice (every 3 to 4 courses depending on the type of immunotherapy) as well as the appearance of side effects throughout the follow-up will be evaluate.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Gilles QUERE
- Telefonnummer: 0298223740
- E-post: gilles.quere@chu-brest.fr
Studera Kontakt Backup
- Namn: Renaud Descourt
- E-post: renaud.descourt@chu-brest.fr
Studieorter
-
-
-
Brest, Frankrike, 29609
- Rekrytering
- CHRU de Brest
-
Kontakt:
- Gilles QUERE
- E-post: gilles.quere@chu-brest.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Major patient
- Metastatic non-small cell lung cancer
- Initiation of anti PDL1 therapy (NIVOLUMAB, PEMBROLIZUMAB or ATEZOLIZUAMB) in daily practice
- No objection made
Exclusion Criteria:
- Autoimmune disease diagnosed prior to initiation of immune checkpoint inhibitor therapy.
- Previous immune-modulating therapy (including corticosteroid therapy greater than 10 mg/day)
- Patient with prior checkpoint inhibitor therapy
- Patient with a contraindication to immunotherapy
- Patient under legal protection
- Refusal to participate
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change of biological markers of immunity under immunotherapy at 6 months
Tidsram: Day 0 and month 6 (M6)
|
Determine the proportion of patients who have or will develop a change in biological markers of immunity under immunotherapy at 6 months or, failing that, at the end of the immunotherapy (FAN and/or RF and/or anti-tissue and/or decrease in acquired complement verified on the difference between 6 months and inclusion, lymphocyte immunophenotyping)
|
Day 0 and month 6 (M6)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Impact on Overall Survival (OS) and Progression Free Survival (PFS)
Tidsram: Day 0 and Six month after (M6)
|
Determine if the presence of biological markers of autoimmunity at initiation or during anti-PD1/PDL1 immunotherapy influences overall survival or progression-free survival.
|
Day 0 and Six month after (M6)
|
Impact on autoimmune toxicity
Tidsram: Day 0 and month 6 (M6)
|
Determine if the presence of biological markers of autoimmunity (at inclusion, at 6 months or at progression) is associated with autoimmune toxicity (any clinical or biological autoimmune event regardless of its grade). Determine if the presence of biological markers of autoimmunity (at inclusion, at 6 months or at progression) is associated with autoimmune toxicity (any clinical or biological autoimmune event regardless of its grade). |
Day 0 and month 6 (M6)
|
Impact of complement
Tidsram: Day 0 and month 6 (M6)
|
Determine if the decrease in complement at 6 months is associated with autoimmune toxicity.
|
Day 0 and month 6 (M6)
|
Impact of autoimmune toxicity on OS
Tidsram: Day 0 and month 6 (M6)
|
Determine if the occurrence of autoimmune toxicity during anti-PD1/PDL1 immunotherapy for non-small cell lung cancer influences the patient's overall survival.
|
Day 0 and month 6 (M6)
|
Impact of autoimmune toxicity on PFS
Tidsram: Day 0 and month 6 (M6)
|
Determine if the occurrence of autoimmune toxicity during anti-PD1/PDL1 immunotherapy for non-small cell lung cancer influences the patient's progression-free survival.
|
Day 0 and month 6 (M6)
|
Impact of clinical factors
Tidsram: Day 0 and month 6 (M6)
|
Determine if clinical factors (undernutrition, tumor mass, general condition) at initiation or during anti-PD1/PDL1 immunotherapy influence patient's overall survival and progression-free survival
|
Day 0 and month 6 (M6)
|
Study the clinical factors influencing the immune profile
Tidsram: Day 0 and month 6 (M6)
|
Study the clinical factors influencing the immune profile
|
Day 0 and month 6 (M6)
|
Impact of CRP and lymphopenia
Tidsram: Day 0 and month 6 (M6)
|
Determine if CRP and the presence of initial lymphopenia influence the presence or induction of an immunological abnormality
|
Day 0 and month 6 (M6)
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Immuno-PREDICT ( 29BRC21.0021)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lungcancer
-
Chang Gung Memorial HospitalAvslutad
-
University of ZurichDeep Breath Intelligence (DBI)RekryteringLung-/luftvägssjukdomarSchweiz
-
424 General Military HospitalAvslutad
-
Celularity IncorporatedAvslutadSteg 2 Lung sarkoidos | Steg 3 Lung sarkoidosFörenta staterna
-
Centre Hospitalier Universitaire, AmiensAvslutadHemodialyskomplikation | Lung ultraljudFrankrike
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... och andra samarbetspartnersAktiv, inte rekryterandePre-extensivt läkemedelsresistent lung-TB | Behandling Intolerant multiresistent lung-TB | Icke-responsiv multiresistent lung-TBIndien
-
Pontificia Universidad Catolica de ChileRekryteringLung ultraljud | Öppen bukkirurgiChile
-
University of Colorado, DenverChildren's Hospital Colorado; Food and Drug Administration (FDA)AvslutadHypertoni;Lung;PrimärFörenta staterna
-
University Hospital, LilleAvslutad
-
Papa Giovanni XXIII HospitalAvslutadLungtransplantation | Ex Vivo Lung PerfusionItalien